HC Wainwright & Co. Initiates Coverage On Verona Pharma with Buy Rating, Announces Price Target of $25
HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on Verona Pharma (NASDAQ:VRNA) with a Buy rating and announces Price Target of $25.